Reprogramming Cancer And Competing With China With Earli's Cyriac Roeding

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Cyriac Roeding talks about cofounding and leading Earli, a "bioAI" company using synthetic DNA switches and cancer-binding lipid nanoparticles to transform cancer cells into immune therapy-producing factories in vivo.  Cyriac also discusses China’s newest five-year plan for biotech (2026 to 2030), why U.S. funding cycles are pushing innovation offshore, and how a U.S. sovereign wealth fund could support preclinical and early-stage drug development leadership at home.   Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.   Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: [email protected] Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/